BRAINPEPS

Crossing the blood-brain barrier (BBB) is the biggest obstacle to the development of new drugs with brain targets.

The majority of drug candidates for a central nervous system disease are abandoned in the clinical phase because they fail to reach their target.

BRAINPEPS' technology has developed a cell-penetrating peptide (CPP) that can be used in a plug-and-play manner using a cross-linker and that promotes the passage of the BBB to allow drug candidates to reach their brain target.

• An innovative CPP, whose three-dimensional conformation has been optimized for the passage of the BBB
• Increase in BBB passage by +10x compared to other known CPPs
• Diversity of application with a coupling system via a cross linker.

• Chemical grafting of the cell penetrating peptide to the brain-targeted drug candidate or production of the fusion protein.
• Evaluation of toxicity and efficacy of passage on a differentiated cell blood-brain barrier model in comparison with other solutions.
• Evaluation of brain penetration in vivo after intravenous injection in mice using the conjugation of CPP BRAINPEPS with a temperature biosensor (neurotensine).
• System and model ready for efficacy testing with drug candidates: first underway with a nanobody in a tauopathy application.

The applications concern all nervous system pathologies whose management requires the passage of molecules of interest across the BBB. They also cover the development of brain biomarkers for these diseases.

• Neurological diseases (Alzheimer's, Parkinson's, etc)
• Pain management
• Glioblastoma
• Psychiatric diseases